Cyrano Therapeutics has acquired an exclusive license to use Resyca’s soft mist nasal spray technology for delivery of CYR-064 intranasal theophylline for the treatment of post-viral hyposmia. According to the announcement, the Phase 2 FLAVOR study of CYR-064 that was initiated in 2023 has been using an Ursatec spray pump enhanced with the Resyca technology for delivery of the nasal spray.
Cyrano says that it expects to have top line data from the FLAVOR trial in the second half of this year. Kyorin recently acquired an option to license the Japanese rights to CYR-064 for the treatment of loss of smell. Cyrano also recently announced that an investigator-led Phase 1 study of CYR-064 in Parkinson’s disease patients is underway.
Resyca is a joint venture between Bespak and Medspray. Those companies announced the addition of soft mist nasal device development to their agreement in January 2024. In October 2024, Resyca and Aero Pump announced the availability of the Ultra Soft Nasal Pump Spray, which integrates Resyca soft mist nasal technology into an Aero Pump device.
Cyrano CEO Rick Geoffrion commented, “This agreement with Resyca enables us to enhance the efficacy of our treatment for patients experiencing chemosensory dysfunction by delivering our proprietary formulation through their advanced soft mist technology. Resyca’s soft mist technology plays a critical role in optimizing the deposition and delivery of CYR-064 in the olfactory region to maximize its therapeutic potential. This advanced delivery system has been integral to our Phase 2 FLAVOR trial, which is currently wrapping up enrollment.”
Resyca CEO Remko Beimers said, “Our patented soft mist nasal technology enables advanced drug delivery for both biologics and small molecules. Partnering with Cyrano Therapeutics aligns with our mission to drive innovation in drug delivery solutions. We believe this collaboration will help patients regain their sense of smell, achieve better treatment outcomes, and create a barrier to entry for any future competitors.”
Read the Resyca and Cyrano Therapeutics press release
